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Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most important
multidrug-resistant nosocomial pathogens worldwide with infections leading to high
rates of morbidity and mortality, a significant burden to human and veterinary clinical
practices. The ability of S. aureus colonies to form biofilms on biotic and abiotic surfaces
contributes further to its high antimicrobial resistance (AMR) rates and persistence in
both host and non-host environments, adding a major ecological dimension to the
problem. While there is a lot of information on MRSA prevalence in humans, data
about MRSA in animal populations is scarce, incomplete and dispersed. This project
is an attempt to evaluate the current epidemiological status of MRSA in Portugal by
making a single case study from a One Health perspective. We aim to determine the
prevalence of MRSA in anthropogenic sources liable to contaminate different animal
habitats. The results obtained will be compiled with existing data on antibiotic resistant
staphylococci from Portugal in a user-friendly database, to generate a geographically
detailed epidemiological output for surveillance of AMR in MRSA. To achieve this, we
will first characterize AMR and genetic lineages of MRSA circulating in northern Portugal
in hospital wastewaters, farms near hospitals, farm animals that contact with humans,
and wild animals. This will indicate the extent of the AMR problem in the context of local
and regional human-animal-environment interactions. MRSA strains will then be tested
for their ability to form biofilms. The proteomes of the strains will be compared to better
elucidate their AMR mechanisms. Proteomics data will be integrated with the genomic
and transcriptomic data obtained. The vast amount of information expected from this
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omics approach will improve our understanding of AMR in MRSA biofilms, and help
us identify new vaccine candidates and biomarkers for early diagnosis and innovative
therapeutic strategies to tackle MRSA biofilm-associated infections and potentially other
AMR superbugs.
Keywords: antimicrobial resistance, surveillance, MRSA, One Health, omics
INTRODUCTION
Staphylococcus aureus is a Gram-positive facultative anaerobe
frequently present in the natural human microbiota of the nose
and skin that can cause a range of illnesses from minor skin
infections and food poisoning to life-threatening diseases such
as pneumonia, toxic shock syndrome and sepsis (Sousa et al.,
2017). The first methicillin-resistant S. aureus (MRSA) was
reported only a year after the introduction of methicillin for
S. aureus treatment (Jevons, 1961). MRSA is resistant to almost
all beta-lactams and frequently carries other major classes of
antimicrobial resistance (AMR).
Most AMR research has been focused on bacteria growing in
planktonic cultures and antimicrobials were originally developed
to target individual bacterial cells. However, it is clear that
bacteria preferentially develop as complex communities called
biofilms (Seneviratne et al., 2012; Penesyan et al., 2015).
Recent advances in proteomics techniques have enabled a
more in-depth analysis of the possible mechanisms responsible
for biofilm AMR and the identification of new anti-biofilm
targets (Seneviratne et al., 2012; Azeredo et al., 2017). The
use of prefractionation techniques to extract subproteomes
significantly enhanced protein identification and coverage
of the biofilm proteome (Seneviratne et al., 2012). Also,
new shotgun proteomics workflows based on high-resolution
tandem mass spectrometry (MS/MS) directly coupled to
high performance liquid chromatography (LC) require less
protein than conventional two-dimensional gel electrophoresis
(2-DE) approaches, allowing a more exhaustive analysis of
proteomes or subproteomes and the performance of label-free
semi-quantitative comparisons (Azeredo et al., 2017).
Staphylococci have for many decades been recognized as the
most frequent cause of biofilm-associated infections (Cihalova
et al., 2015; McCarthy et al., 2015). Since the 1990s the
epidemiological profile of MRSA has been changing significantly.
Its emergence is no longer exclusive to hospitals, as the prevalence
of community-acquired infections is increasing (European
Centre for Disease Prevention and Control [ECDC], 2017a,b). In
fact, several cases of people having had no contact with hospital
environments have been diagnosed with MRSA despite having
no risk factors for contracting an infection by these organisms
(Sousa et al., 2017). In recent years, new genetic lineages of
MRSA have been found associated with companion (Leonard and
Markey, 2008; Coelho et al., 2011), livestock and food-producing
animals, and in various foods (Lee, 2003). However, there is little
information on how MRSA spreads and data about the strains
recovered from environmental sources, animals and human
communities is far from comprehensive. Convergences between
habitats can lead to frequent contact between wild animals,
other animals and humans, potentially increasing risks to human
and animal health. For example, human sources of AMR
determinants could contaminate surrounding areas used as food
sources for wild animals. More MRSA strains are expected to
emerge in the future. The implementation of measures to control
zoonotic pathogens and limit the global emergence of resistance
traits is required. Integration of human and veterinary systems
alone is insufficient as it does not address many structural and
environmental issues critical to health.
Biofilm-associated infections are a significant socio-economic
burden and have emerged as a major public health concern (Sun
et al., 2013; Penesyan et al., 2015). Nearly 80% of all human
infections are biofilm-related and one of their most critical
features is their considerably higher resistance to environmental
stresses, antimicrobials, disinfectants and host immune defenses
(Seneviratne et al., 2012; Sun et al., 2013). Despite major advances
in biofilm research, knowledge on biofilm formation, propagation
and resistance is still very limited and this poor understanding
has hampered the development of antimicrobial drugs that
specifically target biofilms (Penesyan et al., 2015; Venkatesan
et al., 2015).
Antimicrobial resistance acquisition and dissemination rates
are outpacing the drug development pipeline (Harbarth et al.,
2015; O’Neill, 2016). AMR has the potential to affect anyone of
any age in any country (World Health Organization, 2014). If not
adequately addressed, AMR could cause 10 million deaths and
cost 100 trillion dollars by 2050 (O’Neill, 2014, 2016; European
Commission [EC], 2017). Patients with drug-resistant infections
or diseases tend to consume more resources and are sick for
longer periods, increasing the risk of severe outcomes even if
they manage to overcome their main health issue. In addition,
the families and entourage of the ill person also end up suffering
on personal, practical and economic levels (Ellen et al., 2017).
The continuous quantification of the economic burden of these
diseases on the individual and on society in general will show the
direct consequences of AMR on health system budgets, and other
costs that might be associated with losses incurred by different
stakeholders (e.g., patients, carers, and governments) (Angelis
et al., 2015).
When making such estimates the perspective being taken
when considering such scenarios needs to be well defined
(Naylor et al., 2018). The payer/provider perspective juxtaposes
the patient’s perspective, which concerns itself with morbidity,
mortality and the clinical outcomes, and the payer’s perspective,
which focuses on healthcare costs attributable to medical
insurance and tax payers (Naylor et al., 2018). The healthcare
provider’s perspective also needs to be taken into account
to estimate the burden on some providers of healthcare like
hospitals and primary care practices. Finally, the economic or
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societal perspective generally includes the potential impact on the
labor force through decreases in productivity, but also the burden
on carers and patient out-of-pocket expenses (Naylor et al., 2018).
There may be secondary effects of AMR if certain healthcare
procedures involving antimicrobial usage are avoided. In a
systematic literature review, Naylor and Colleagues (2018) found
187 studies estimated the impact on patient health, 75 studies
estimated the payer/provider impact and 11 studies estimated
the economic burden. Overall 64% of the studies reviewed were
single-center studies. The great majority of studies estimating
patient or provider/payer impact used regression analyses. AMR
was found to have a significant impact in 48% of the studies
that estimated mortality burden. Excess healthcare system costs
ranged from non-significant to $1 billion per year, whereas
economic burden varied from $21,832 per case to over $3 trillion
in GDP loss. Median quality scores (interquartile range) for
patient, payer/provider and economic burden studies were 0.67
(0.56–0.67), 0.56 (0.46–0.67), and 0.53 (0.44–0.60), respectively.
AMR has therefore become a cause of international concern not
only due to the actual and future impact it may have on the
population’s health, but also on the costs to healthcare systems
and gross domestic product (GDP), mainly by the decrease in
treatment options.
This project will aim first to provide a better understanding
of MRSA prevalence, burden and dissemination in the One
Health context of human-animal-environment interactions and
then to investigate through proteomics the AMR mechanisms
occurring in MRSA biofilms. By characterizing AMR and genetic
lineages of MRSA circulating in anthropogenic sources in the
North of Portugal, this project will provide epidemiological
surveillance data, compiled and easily accessible to the scientific
community, public health officials, and the general public. The
further proteomic profiling of MRSA biofilms will increase our
knowledge of biofilm-specific AMR mechanisms and identify
potential vaccine candidates and biomarkers for early rapid
diagnosis and new therapeutic strategies.
MATERIALS AND METHODS
Samples
Samples from hospital effluents, and nearby habitats linked to
animal farms and wild animal territories will be collected in the
Portuguese north province of Trás-os-Montes and Alto Douro
annually. Specifically:
(a) Hospital samples will be obtained from the four public
hospitals responsible for the public health of the citizens
of this province – [Hospital Centre of Trás-os-Montes and
Alto Douro (CHTMAD)] – these are located in the cities
of Lamego, Peso da Régua, Chaves, and Vila Real. Ethical
approval and support has been granted by CHTMAD.
(b) Farm samples will be obtained from soils and farmers,
and from animals and their handlers from all the 31
municipalities of the province. The representativeness of
the sample of farms will be calculated after obtaining
the data referring to the type of farms existing by
municipality (e.g., cows, pigs, birds, etc.), and subsequent
randomization of the animal samples of each farm.
(c) Wild animal samples will be collected by groups of hunters
during the wild rabbit and wild boar hunts and by
the Wildlife Recovery Center (Centro de Recuperação
de Animais Selvagens, CRAS) at the University of
Trás-os-Montes and Alto Douro veterinary hospital.
This data will allow us to map, characterize, and monitor
AMR and genetic lineages of MRSA annually, by its presence or
absence in the area. It will also indicate the extent of the problem
of local and regional human-animal-environment interactions
in Trás-os-Montes e Alto Douro (One Health and Eco Health
Concepts).
Furthermore, questionnaires regarding the use of antibiotics
by the participating entities will be sent to them for annual
update – (e.g., hospitals: how many antibiotics have been
prescribed by this entity in the last year?; farms: how many of
your animals have been administrated antibiotics? How many
times has that occurred in the last year?).
MRSA Detection
Staphylococcus aureus and MRSA will be recovered on mannitol
salt agar and oxacillin resistance screening agar base (ORSAB),
respectively. Presumptive S. aureus and MRSA colonies will
be identified based on their morphology and re-isolated. Their
identity will be confirmed by genotyping using molecular
methods and VITEK technology, via PCR amplification of the
nuc and mecA genes. Phenotypic antimicrobial susceptibility
will be tested with the EUCAST disk diffusion and broth
microdilution methods and the presence of corresponding
resistance genes will be investigated by PCR and sequencing. The
clonal relationship of isolates will be assessed by pulsed-field gel
electrophoresis, spa-typing, agr-typing and multilocus-sequence-
typing (MLST).
Data Collection
All data will be compiled and added to a new web-based
application developed so that georeferenced AMR data can be
consulted and visualized by medical professionals, the scientific
community and others that require it. Existing data on antibiotic
resistant staphylococci in Portugal will also be compiled and
included in the database. Similar interfaces exist such as the
ECDC’s Surveillance Atlas of Infectious Diseases and the CDC’s
Antibiotic Resistance Patient Safety Atlas that allow users to
openly interact and manipulate AMR data to customize a variety
of maps and tables. However, finer granularity is intended with
the possibility to retrieve and filter data at the level of sample
collection and isolation details, AMR phenotypic and genotypic
profiles, genetic lineages, biofilm-forming ability, among others.
Additionally, this information should be traceable to available
proteomic, genomic and transcriptomic data of the individual
MRSA strains.
Importantly, as AMR prediction and surveillance spans
many scientific realms (public health, research, agriculture, drug
discovery, etc.), ease-of-use translational tools and data sharing
are increasingly needed, requiring a collective dedication to
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standardization. Although several global surveillance programs
exist that monitor AMR (McArthur and Tsang, 2017), genotypic
data is not found in their datasets and accessible databases that
combine genotypic and phenotypic AMR data for pathogens
in environmental, agricultural, and clinical settings are still not
available. Hence, the generation of these informatics resources
are of high priority considering their value for epidemiology,
antimicrobial stewardship, and drug discovery (McArthur and
Tsang, 2017).
Analysis of the Outcomes
All isolated MRSA strains will be tested for their ability to form
biofilms. The antimicrobial susceptibility of any biofilm-forming
strains will be re-assessed. The proteomes of a number of
biofilm-forming MRSA strains will then be characterized.
Different subproteomes of MRSA biofilms will be analyzed
and compared using both electrophoretic and direct mass
spectrophotometric approaches (2-DE-LC-MS/MS and shotgun
LC-MS/MS) to identify differentially expressed proteins induced
by antimicrobials. The strains selected for proteomic analyses will
also be characterized at the genomic and transcriptomic level
by whole genome sequencing and RNA sequencing. All omics
data will be analyzed and integrated using bioinformatics tools.
Several institutions including universities and laboratories will
cooperate in this data integration task and all the collaborating
international research groups will provide support for data
interpretation (Figure 1). Biosafety standards will be respected
at all stages of the work.
PRELIMINARY AND EXPECTED
RESULTS
One Health Focus on
Livestock-Associated MRSA in Portugal
and Europe
In the past decade, our research group has been surveying AMR
in bacteria from a great diversity of environments, collecting over
4,000 samples from more than 75 different sources (humans,
wastewaters, food-producing animals, pets, and wild animals),
amounting to over 5,000 bacterial isolates. High levels of AMR
to critically important drug classes and high rates of clinically
relevant multi-resistant strains in non-synanthropic animal
species have been found (Marinho et al., 2016). Portugal is one of
the countries with highest rates of MRSA and about 44% of the
Portuguese hospital S. aureus isolates are methicillin-resistant,
the second highest rate in Europe (European Centre for
Disease Prevention and Control [ECDC], 2017a,b). Our recently
published research reveals that MRSA are common in the
Portuguese animal communities (Coelho et al., 2011; Marinho
et al., 2016) and that the environment and wild animals can be a
reservoir or a vehicle of transport for MRSA (Sousa et al., 2017).
Currently our research group is one of the few in Portugal that
studies antibiotic resistance in wild animals (Oliveira et al., 2010;
Clemente et al., 2015; Dias et al., 2015; Jones-Dias et al., 2016;
Serrano et al., 2017). For example, we reported the first MRSA
isolate of the CC398 (spa-type t899) lineage from a wild animal in
this country, recovered from a wild boar (Sus scrofa). The isolate
is agr-type I and carries a multi-antibiotic-resistance phenotype,
including against beta-lactams (mecA gene), tetracycline and
ciprofloxacin (Sousa et al., 2017).
We do not know how AMR flows through the environment.
This proposal is the next step to investigate the flow of AMR
in MRSA and to establish a publicly available, user-friendly
database that compiles and integrates the new and existing
data on MRSA in Portugal. To illustrate the approach, we can
take the spread of the livestock-associated MRSA (LA-MRSA)
ST398 as an example. MRSA are indeed becoming frequent
in veterinary clinics, in farms, and in livestock animals. In
recent years, this particular MRSA clone associated with food
production has spread in Europe and is emerging worldwide.
Since its discovery, there has been a steady flow of reports of
LA-MRSA ST398 among livestock, especially pigs, in numerous
European countries (Loeffler et al., 2009). People exposed to
livestock are at greater risk of being colonized, and subsequently,
infected with LA-MRSA ST398, especially if they are working on
farms with a high prevalence. The occupational risk for people
exposed to livestock, and those in direct contact with them, has
been repeatedly shown. There is not enough data to compare
studies in Portugal alone, but if studies from other countries
are considered, we can say that LA-MRSA infections may occur
outside and independently of hospitals (Pomba et al., 2010).
LA-MRSA CC398 is able to cause the same kind of infections
that human-adapted MRSA (HA-MRSA) causes in humans.
Comparative genome analysis has shown that LA-MRSA has
FIGURE 1 | Timeline of case study based on the comparative assessment of antimicrobial resistance of MRSA isolates from Portugal.
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evolved from HA-MRSA, and the jump from humans to livestock
has been clearly associated with several genetic changes (Price
et al., 2012). We will further analyze the proteome and the
transcriptome associated to this strain and compare it to the
online data on CC398 strains to confirm whether this is an
LA-MRSA or a genetically distinguishable strain with zoonotic
potential originating from wild animals. Whatever the result, the
evolution and re-adaptation of these bacteria to various animal
or human populations pose a potential health risk requiring close
surveillance.
Beyond surveillance studies, our research group has
investigated AMR mechanisms by characterizing a range of
resistant strains of interest through proteomic approaches in
MRSA (Monteiro et al., 2012, 2015) and other bacterial species
(Pinto et al., 2010; Radhouani et al., 2010, 2012; Correia et al.,
2014, 2016; Goncalves et al., 2014; Ramos et al., 2015, 2016;
Monteiro et al., 2016). However, these proteomic studies, and
most AMR research in general, have focused on bacteria growing
in planktonic cultures and hence overlooked biofilm-specific
AMR mechanisms. These are known to be distinct from the
well-characterized intrinsic mechanisms that occur at the
cellular level, operating additively to the latter, in a transient and
reversible manner, resulting in up to 1000-fold higher resistance
levels (Sun et al., 2013; Penesyan et al., 2015; Azeredo et al.,
2017). Hence, biofilm-specific mechanisms need to be considered
when developing new strategies to combat infectious diseases
(Sun et al., 2013; Penesyan et al., 2015).
The objective is to promote collaboration between several
public entities as well as different stakeholders from industry and
media. We aim to produce information by studying AMR in
bacteria from wild animals with zoonotic potential. The potential
impacts are both internal, by generating more precise knowledge
and collaboration, and external, by improving animal, human,
and environmental health in the long term (Figure 2). All the
MRSA data generated by studying isolates from wild animals
will be disseminated according to the principles of One Health
information sharing.
Scientific Tasks and Challenges
All S. aureus strains should be isolated and MRSA strains
identified. Phenotypic and genotypic AMR profiles of all strains
should be determined, and molecular typing of strains should
be completed. The database should be online and functional.
All data on methicillin-sensitive S. aureus and MRSA isolates
characterized in this project, together with existing data from
isolates from Portugal, should be compiled in the database.
Testing for biofilm formation and antimicrobial susceptibility
should be completed for all MRSA isolates. Strains for further
omics approaches should be chosen.
When considering the MRSA issue, we automatically think
about outbreaks in the clinical setting. The truth is that this
worrisome organism is everywhere, in human clinical isolates,
in healthy people who work in clinical or care facilities, in
livestock animals and their handlers, in food production and
slaughter lines, in wastewater, garbage, and as recently shown,
in wild animals. This situation is clearly not new and not
wholly unexpected, but in Portugal this environmental MRSA
FIGURE 2 | Graphical abstract of case study based on the comparative
assessment of antimicrobial resistance of MRSA isolates from Portugal.
flow is problematic. Our research team has been trying to
draw attention to this issue by centering our investigations
on the veterinary and environmental aspects. As well as the
knowledge and expertise we have accumulated within our
team, factors that contributed positively to this work were the
collaborations between laboratories and associations, and the
individual scholarships from the Portuguese Foundation for
Science and Technology (FCT) that made it possible for our
students to carry out field work and have access to specialized
laboratories. Many factors were challenging at the outset like
collecting the samples, often in bad weather conditions. However,
with the cooperation of six faculties, stakeholders from industry
and media, and Portuguese governmental initiatives we are
continuing our surveillance of AMR bacteria recovered from wild
animal populations.
Strategy for One Health Knowledge
Sharing
Two strategic axes have been established to reduce the risk
of AMR caused by the use of antibiotics in animals. The
aim of the public health protection axis is to reduce the
impact of administered veterinary antibiotics on AMR spread.
The therapeutic preservation axis is designed to promote
the sustainability and efficacy of antimicrobial use. Our plan
reflects EU policies because the opinions of a wide range of
stakeholders have been taken into account with input from
academia and industry, and from practitioners like veterinarians,
pharmacists and farmers. One Health learning is expected to
involve individual researchers and institutions by the creation
of long-term supportive interdisciplinary infrastructures and
professional networks.
Effective communication is essential to underpin such
a wide-ranging approach. Regular scientific meetings for
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consortium updates will complement international congresses to
disseminate and discuss findings. Engagement will extend into
the community through lectures to high school and university
students, and take advantage of social and traditional media
outlets. Partners in the countryside will be targeted by providing
educational workshops for hunters and cooperating with the
League for Nature Protection. Professional guidelines and good
practice will be observed, disseminated, promoted and reinforced
for all practitioners (distributors, veterinarians, and farmers).
For example, active participation in the National Action Plan
for Antibiotics Use Reduction in Animals will help to trace and
validate veterinary prescription and requisition and to harmonize
the register of all medicines administered at farms. With adequate
support and training of all professions dealing with animal health
and animal production, better selection and use of antibiotics will
be promoted, and innovations and alternatives can be explored.
The promotion of investigation, innovation and technological
exchanges to incentivize the development of alternative means
of treatment, whenever possible and a reinforced monitoring,
audits and controls are very important actions to fight against
AMR. Research outcomes will be of high quality as we will
find out which AMR bacterial variants are associated with
each focus of infection and each animal species in a particular
habitat. A galvanized network of specialists should more able
to prompt the authorities to take action to better regulate
antibiotic prescription in hospitals and care facilities (for humans
and animals) and on farms, and to take control over how
antimicrobials are disposed of, especially when there is a risk of
polluting the environment.
Antimicrobial resistance is estimated to cause 25,000 deaths
annually and cost over €1.5 billion in healthcare expenses
and productivity losses in Europe alone (O’Neill, 2014;
European Commission [EC], 2017). In general, higher resistance
frequencies are reported by countries in eastern and southern
Europe (European Centre for Disease Prevention and Control
[ECDC], 2017b). Given the severity of the consequences, MRSA
is now a public health priority in Europe and is also one of the
highest-priority pathogens in the WHO global priority list to
guide research, discovery and development of new antibiotics.
The high incidence of MRSA adds to the overall clinical
and economic burden in hospitals, causing prolonged hospital
stays and higher mortality, mainly due to delayed initiation
of appropriate therapy and less effective alternative treatment
regimens (O’Neill, 2016; European Centre for Disease Prevention
and Control [ECDC], 2017a,b). Given this, there is an impetus
to understand the Portuguese situation in more depth, and
precision. To facilitate uptake of results and meta-analysis we will
base our research on the recommendations of Naylor et al. (2018)
by clearly defining data collection and use wherever possible
from representative samples of the population studied. Potential
TABLE 1 | Proposed One Health activities, aims and monitoring to implement and integrate knowledge to evaluate the current methicillin resistant Staphylococcus
aureus situation and estimate its economic burden at the formulation stage of the policy cycle.
One Health initiative specific aims regarding five main activities Monitoring1 (transversal activity) One Health initiative main aim
Thinking • Stipulate the dimensions that need coverage, and
balance different areas of knowledge and multiple
perspectives.
• Reflect upon the initiative-to-environment match.
• Reflect upon the best integrated health approach.
• Consider all the system features and targets and,
sustainability and socio-ecological-economic impacts.
• Think and decide upon relevant performance indicators
for each One Health Initiative main activity.
Planning During all the initiative phases the following are
of extreme relevance to be under monitoring
and assessment for the need for change,
development and, innovation:
• Establish common aims that will lead to stakeholder and
actor engagement while monitoring, self-assessing and
updating each plan when needed.
• Research Problem and Design
• Team structures
• Social and leadership structure
• Social and leadership skills
• Competence/Skills
• Resource allocation
• Focus and innovation
Set guidelines that allow for Policy
Formulation. (This is possible through
the results obtained during the five
activities. These will allow evidence
which will point out solutions to the
AMR problem, and recommendations
on how to improve its situation.)
Working • Stimulate the inclusion and collaboration of each
stakeholder of the initiative, broadening its impact while
balancing its transdisciplinary (cultural, social, and
economic) – nature.
Sharing • Stimulate systematic general information/awareness
sharing, through data and information sharing and
development of methods and stimulation of results
sharing. These activities intend to develop institutional
memory and resilience ability.
Learning • Create a general and direct multilevel (individual level,
team level and organizational level) learning environment
supportive of adaptive and generative learning.
1 Implies monitoring and assessing the processes and results implied in each suggested dimension implied in each initiative activity. This is intended to stimulate the
initiatives reflexivity and adaptiveness ability. Adapted from Hitziger et al. (2018).
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confounding factors and biases will be carefully considered when
choosing the methodology. All steps of data collection and
processing will be clearly recorded. Wider impacts on healthcare
systems and economics will be estimated where possible with
explanation and justification of any models chosen (Table 1).
DISCUSSION
One Health Initiative to Address AMR in
Portugal
The One Health approach is the European Commission strategy
to tackle AMR, as it recognizes that the health of people, animals
and the environment are inextricably linked. This project intends
to answer several One Health evaluation questions. (i) How can
the spread of AMR be avoided in both human and veterinary
medicine? (ii) How can we define the role of wildlife in AMR
gene flow? (iii) What steps should we advocate to disseminate
our future results? And (iv) How should this issue be addressed
in terms of public health?
By involving different universities and stakeholders from
industry this project has a One Health attitude from the
outset. Different scientific work packages will address the
following topics: isolation and identification of strains; genomic
and genotypic studies; demographic and socioeconomic
characterization; sequencing studies; phenotypic studies;
proteomic and transcriptomic analysis; results verification and
homologation.
This project will consolidate knowhow in the isolation
and identification of MRSA strains from different ecosystems
in Portugal. Several collaborations will be maintained and
developed between different research groups through this and
other projects. This will allow the creation of a bacterial
collection with hundreds of strains comprehensively analyzed
with genomics and proteomics tools. Knowledge and expertise
in using these tools to characterize AMR bacteria will
be consolidated, particularly in genotyping techniques by
enterobacterial repetitive intergenic consensus PCR and MLST.
Purified bacteriocins will be characterized biochemically by
MALDI-TOF MS, N-terminal amino acid sequencing by Edman
degradation, and sequencing by MALDI TOF/TOF MS. The use
of these techniques and the associated equipment will allow us to
establish standard protocols for proteomics.
The results of this investigation may add to our knowledge
on the occurrence of MRSA strains and the genetic lineages
circulating in our surroundings. A more precise local estimate
of AMR due to the MRSA burden can inform policy and shape
the initiatives to monitor, prevent, treat and limit the spread of
resistant infections.
The potential impacts of this case study will lead to better
knowledge and collaboration in our interdisciplinary consortium
and extended network as well as improvements in animal, human
and environmental health.
This project builds on previous efforts of European
Commission programs and other programs worldwide and aims
to answer priority questions in research and innovation for
infectious diseases. First, AMR, genetic lineages and biofilm-
forming ability of MRSA strains circulating in anthropogenic
sources will be characterized, adding to the emerging picture of
the extent of the AMR problem in the context of human-animal-
environment interactions. Data will be made available in a free,
user-friendly online platform, providing a geoepidemiological
output. Further proteomic profiling of MRSA biofilms, integrated
with high-throughput genomics and transcriptomics, will
provide a large amount of data that will extend the currently
limited knowledge on biofilm-specific AMR mechanisms. If
this is successful, new molecular candidates for vaccines or
biomarkers will be identified that could be developed for
early rapid diagnosis and innovative therapeutic strategies
to tackle biofilm-associated infections in MRSA and other
superbugs with high burden impact. Such an investment
in research and innovation taking into consideration the
multi-layered burdens of MRSA will improve prevention and
treatment and will help us to remain active and vigilant, to
develop new, safer and more effective medical treatments, to
maintain health and to ensure the viability of health systems.
Hopefully this will stimulate more concerted action to reduce
the prevalence of MRSA and AMR in Portugal and further
afield.
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